Speclipse, Inc., is the medical device developer of the world’s first cancer diagnostic solution based on laser-induced plasma spectroscopy (LIPS) and artificial intelligence (AI) technology. Our core technology, Spectra-Scope®, embodies a real-time, non-invasive, in-vivo diagnosis of skin cancers without compromising efficacy and accuracy while preventing unnecessary biopsies. We are committed to providing innovative medical technology to assist in challenging diagnosis cases—and it is our mission to continue to improve our technology so physicians can spend more time focusing on their patients and making accurate diagnoses.